CTTH's principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases. The Company believes that its technology...
CTTH's principal asset is a unique and novel patented drug delivery technology, an orally administered, fast dissolving thin film (the "Wafer"). This technology platform will target both the human and veterinarian (pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in major markets such as pain management. The Oral Thin Film (Wafer) formulation is protected by 3 Canadian, 2 U.S. patents and over 59 patents pending or granted worldwide.
Mostrar más